Allen & Overy, Cravath Guide $4.3B Fresenius-Akorn Combo
Fresenius Kabi inked a proposed $4.3 billion deal to pick up Akorn, a maker and marketer of prescription and over-the-counter drugs that complement Fresenius' injections-focused products, in an arrangement advised by...To view the full article, register now.
Already a subscriber? Click here to view full article